ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
종목 코드 ADMA
회사 이름ADMA Biologics Inc
상장일Oct 17, 2013
CEOMr. Adam S. Grossman
직원 수677
유형Ordinary Share
회계 연도 종료Oct 17
주소465 State Route 17
도시RAMSEY
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호07446
전화12014785552
웹사이트https://www.admabiologics.com/
종목 코드 ADMA
상장일Oct 17, 2013
CEOMr. Adam S. Grossman
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음